Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015)
Incyte (INCY) reported Non-Current Deffered Revenue of $2.9 million for Q3 2015, down 81.76% on a YoY basis from $15.7 million in Q3 2014, and down 52.84% quarter-over-quarter from $6.1 million in Q2 2015.
Incyte (INCY) Non-Current Deffered Revenue (2010 - 2015) Analysis & Trends
Incyte has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $2.9 million in Q3 2015.
- For the quarter ending Q3 2015, Non-Current Deffered Revenue fell 81.76% year-over-year to $2.9 million; the trailing twelve-month figure through Sep 2015 stood at $2.9 million (down 81.76% YoY), and the FY2014 full-year result was $12.5 million, down 50.68% from the prior year.
- Non-Current Deffered Revenue for Q3 2015 stood at $2.9 million, down from $6.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $154.5 million in Q1 2011, with the low at $2.9 million in Q3 2015.
- Historically, Non-Current Deffered Revenue has averaged $51.4 million across 5 years, with a median of $31.8 million in 2013.
- Annual changes were most pronounced in 2013 — Non-Current Deffered Revenue plunged 33.63% — and 2015, when it plunged 81.76%.
- Incyte's Non-Current Deffered Revenue stood at $104.3 million in 2011, then slumped by 63.34% to $38.2 million in 2012, then slumped by 33.63% to $25.4 million in 2013, then plunged by 50.68% to $12.5 million in 2014, then sank by 77.07% to $2.9 million in 2015.
- The last three Non-Current Deffered Revenue figures came in at $2.9 million (Q3 2015), $6.1 million (Q2 2015), and $9.3 million (Q1 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 2.87 Mn |
| Jun 30, 2015 | 6.08 Mn |
| Mar 31, 2015 | 9.30 Mn |
| Dec 31, 2014 | 12.51 Mn |
| Sep 30, 2014 | 15.73 Mn |
| Jun 30, 2014 | 18.94 Mn |
| Mar 31, 2014 | 22.15 Mn |
| Dec 31, 2013 | 25.37 Mn |
| Sep 30, 2013 | 28.58 Mn |
| Jun 30, 2013 | 31.80 Mn |
| Mar 31, 2013 | 35.01 Mn |
| Dec 31, 2012 | 38.23 Mn |
| Sep 30, 2012 | 54.06 Mn |
| Jun 30, 2012 | 70.80 Mn |
| Mar 31, 2012 | 87.54 Mn |
| Dec 31, 2011 | 104.27 Mn |
| Sep 30, 2011 | 121.01 Mn |
| Jun 30, 2011 | 137.75 Mn |
| Mar 31, 2011 | 154.48 Mn |
| Dec 31, 2010 | 171.22 Mn |